Modality
Peptide
MOA
BETi
Target
GIP-R
Pathway
Checkpoint
Endometrial CaAngelmanFabry
Development Pipeline
Preclinical
~Dec 2021
→ ~Mar 2023
Phase 1
~Jun 2023
→ ~Sep 2024
Phase 2
Dec 2024
→ Jan 2029
Phase 2Current
NCT06884625
1,943 pts·Angelman
2024-12→2029-01·Completed
NCT03711534
2,331 pts·Endometrial Ca
2025-08→TBD·Terminated
4,274 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-01-012.8y awayPh3 Readout· Angelman
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2029-01-01 · 2.8y away
Angelman
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06884625 | Phase 2/3 | Angelman | Completed | 1943 | Safety |
| NCT03711534 | Phase 2/3 | Endometrial Ca | Terminated | 2331 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-1564 | Biogen | Phase 2 | PSMA |